CDXS

Codexis, Inc.

$2.49

-0.04 (-1.58%)

Mkt Cap 226.33M

Volume 850,535

52W Range 0.96-3.87

Sector Healthcare

Beta 2.53

EPS (TTM) -0.37

P/E Ratio -3.23

Revenue (TTM) 78.09M

Rev Growth (5Y) +0.4%

EPS Growth (5Y) N/A

AlphaQuality · Grade · Gated

Stable Earnings Power

13.9 / 100 pillar composite (overridden)

Company Description

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Track Record

Showing latest 4 periods • Swipe for more

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	70.39M	59.34M	70.14M	138.59M	104.75M	69.06M	68.46M	60.59M	50.02M	48.84M	41.80M	35.31M
Net Income	(43.97M)	(65.28M)	(76.24M)	(33.59M)	(21.28M)	(24.01M)	(11.94M)	(10.88M)	(23.00M)	(8.56M)	(7.58M)	(19.07M)
EPS	-0.50	-0.89	-1.12	-0.51	-0.33	-0.40	-0.21	-0.21	-0.50	-0.21	-0.19	-0.50
Free Cash Flow	(23.85M)	(53.72M)	(57.06M)	2.98M	(28.09M)	(20.21M)	(16.29M)	(16.86M)	(9.75M)	(3.59M)	N/A	N/A
FCF / Share	-0.27	-0.73	-0.84	0.05	-0.44	-0.34	-0.29	-0.32	-0.21	-0.09	N/A	N/A
Operating CF	(19.38M)	(49.41M)	(52.64M)	11.28M	(14.27M)	(16.46M)	(12.56M)	(14.09M)	(8.76M)	(2.70M)	N/A	N/A
Total Assets	147.80M	149.01M	136.56M	250.39M	246.38M	221.65M	149.07M	78.28M	53.62M	35.65M	N/A	N/A
Total Debt	73.21M	59.90M	16.02M	43.64M	47.65M	24.95M	26.12M	61,000	302,000	425,000	N/A	N/A
Cash & Equiv	50.79M	19.26M	65.12M	113.98M	116.80M	149.12M	90.50M	53.04M	31.22M	19.24M	N/A	N/A
Book Value	50.53M	66.93M	86.61M	144.80M	164.39M	170.10M	105.52M	56.31M	24.55M	19.10M	N/A	N/A
Return on Equity	-0.87	-0.98	-0.88	-0.23	-0.13	-0.14	-0.11	-0.19	-0.94	-0.45	N/A	N/A

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Revenue	15.25M	38.91M	8.60M	15.33M	7.54M	21.46M	12.83M	7.98M	17.07M	26.56M	9.28M	21.32M
Net Income	(8.70M)	9.60M	(19.61M)	(13.27M)	(20.69M)	(10.38M)	(20.64M)	(22.75M)	(11.51M)	(7.19M)	(34.91M)	(11.52M)
EPS	-0.10	0.11	-0.22	-0.16	-0.25	-0.13	-0.29	-0.32	-0.16	-0.10	-0.50	-0.17
Free Cash Flow	(13.33M)	19.57M	(7.88M)	(20.48M)	(15.05M)	(18.24M)	(13.99M)	(12.56M)	(8.92M)	(10.66M)	(16.98M)	(17.67M)
FCF / Share	-0.15	0.22	-0.09	-0.24	-0.18	-0.22	-0.19	-0.18	-0.13	-0.15	-0.24	-0.26
Operating CF	(13.15M)	20.09M	(7.70M)	(17.97M)	(13.80M)	(16.47M)	(12.98M)	(12.17M)	(7.79M)	(11.04M)	(16.30M)	(16.09M)
Total Assets	129.37M	147.80M	123.96M	138.25M	128.89M	149.01M	148.18M	132.01M	149.56M	136.56M	154.46M	206.76M
Total Debt	72.90M	73.21M	68.62M	68.98M	59.50M	59.90M	41.85M	42.53M	43.21M	16.02M	19.98M	41.01M
Cash & Equiv	37.00M	50.79M	25.84M	26.76M	18.32M	19.26M	37.45M	18.59M	58.05M	65.12M	74.58M	92.09M
Book Value	43.23M	50.53M	38.54M	55.63M	49.63M	66.93M	73.40M	61.45M	79.27M	86.61M	91.51M	124.13M
Return on Equity	-0.20	0.19	-0.51	-0.24	-0.42	-0.16	-0.28	-0.37	-0.15	-0.08	-0.38	-0.09